Navigation Links
Paratek Pharmaceuticals Announces Expanded FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline
Date:5/1/2013

BOSTON, May 1, 2013 /PRNewswire-iReach/ -- Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline, as a Qualified Infectious Disease Product (QIDP) for the treatment of complicated Urinary Tract Infections (cUTI).  This QIDP designation is applicable for both intravenous (IV) and oral formulations of omadacycline.

The QIDP designation provides Paratek access to certain incentives, including priority review associated with a New Drug Application (NDA) submission, eligibility for fast-track status for smaller population studies targeting certain resistant organisms, and a five-year extension of exclusivity under the Hatch-Waxman Act upon FDA approval of omadacycline. This designation is in addition to that announced by Paratek on January 3, 2013 granting QIDP status for IV and oral formulations of omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

The QIDP designation, which the Company believes is a first for an orally available antibiotic for the treatment of cUTI, is provided under the Generating Antibiotic Incentives Now Act (GAIN Act), which was enacted in July 2012 under the Food and Drug Administration Safety and Innovation Act (FDASIA), formerly known as Prescription Drug User Fee Act V (PDUFA V).  Experts have noted that there is a serious unmet need for new oral antibiotics to treat multi-drug resistant (MDR) bacteria such as E. coli that occur in cUTI and other infections.  In studies conducted to date, omadacycline achieves high concentrations in the urinary tract following oral dosing and retains activity against MDR E. coli and other bacteria common to community-acquired cUTI.  Paratek plans to conduct a cUTI Phase 2 clinical study with omadacycline.  '/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
2. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
3. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
4. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
5. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
6. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
7. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
8. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
9. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
11. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Research and Development Trend Forecast of Pharmaceutical Equipment Market ... Research and Development Trend Forecast of Pharmaceutical ... mainly analyzes China,s pharmaceutical equipment ... & demand, competition landscape, and business performance of domestic ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
... Diamyd Medical AB ( http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, ... DIAM B)(OTC: DMYDY)announced today that the Swedish Medical Products,Agency (MPA) ... the therapeutic diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ...
... Company Initiates Phase 2a Trial in Patients with Stable Asthma ... Exercise-Induced Bronchoconstriction -, ... clinical program studying an investigational treatment targeting,interleukin-9 (IL-9) has advanced ... The company initiated a Phase 2a clinical trial designed to,assess ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma 2
(Date:8/31/2014)... 2014 Brook Forest Voices , ... “Simplicity & Sophistication: Short Stories of Wisdom and Kindness ... Dr. James W. Jackson author, speaker, humanitarian and cultural ... compresses his vast volume of meticulously handwritten notes ... 150 countries on behalf of Project C.U.R.E . ...
(Date:8/31/2014)... With the NCAA set to undergo ... an interview with Yale University Associate Athletic Director Steve ... approach to ensuring student-athlete experience that is consistent with ... a number of key factors that contribute to a ... factor in creating this culture seems simple at first. ...
(Date:8/31/2014)... 31 August 2014: Wine only protects against cardiovascular disease ... the In Vino Veritas (IVV) study presented at ESC ... Republic. , Professor Taborsky said: "This is the first ... wine on markers of atherosclerosis (1) in people at ... moderate wine drinking was only protective in people who ...
(Date:8/30/2014)... 2014: A new method to predict the optimal ... presented at ESC Congress today by Dr Benjamin Dahan ... 350 AEDs located in public places for optimal prevention ... Dahan said: "Out of hospital cardiac arrest is a ... between 50 and 100 per 100 000 in the ...
(Date:8/30/2014)... Barcelona, Spain Sunday 31 August 2014: A ... wristwatch and powered by heart motion was presented ... from Switzerland. The prototype device does not require ... in the Cardiovascular Engineering Group at ARTORG, University ... factor in today,s medical implants. Once they reach ...
Breaking Medicine News(10 mins):Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Wine only protects against CVD in people who exercise 2Health News:New method predicts optimal number and location of AEDs 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2
... HILLS, Calif., June 11 The Jonsson Cancer,Center ... raising,private funds for highest priority cancer research, hosts ... 21, at the Beverly Wilshire Hotel. FOX,Broadcasting Company ... Humanitarian Award. Jimmy Kimmel hosts the event and ...
... LAUREL, N.J., June 11 MedQuist Inc.,(Pink Sheets: MEDQ.PK). ... the District of New Jersey dismissed the South Broward ... and good cause shown,within 60 days, to reopen the ... in the process of informing the court that the ...
... Institute of Allergy and Infectious Diseases (NIAID), part of the ... George W. Bush with the Presidential Medal of Freedom at ... , The White House noted today that Dr. Fauci ... knowledge. His efforts to advance our understanding and treatment of ...
... PLAINS, NY Experts from throughout the United States will ... the growing crisis of preterm birth. , The conference, ... RADM, USPHS and the Eunice Kennedy Shriver National Institute of ... 16 and 17 in Rockville, MD. It is a ...
... While consumers are increasing demand for pork produced ... such conditions carry bacteria and parasites associated with ... A comparison of swine raised in antibiotic-free and ... outdoors without antibiotics had higher rates of three ...
... some into remission, study says , , WEDNESDAY, June ... golimumab to weekly doses of methotrexate helped most ... into remission, two new studies show. , The ... biologic therapy drug, were scheduled to be presented ...
Cached Medicine News:Health News:American Idol Winner David Cook to Perform at and Jimmy Kimmel to Host Jonsson Cancer Center Foundation's 'Taste for a Cure' on June 21 2Health News:MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO 2Health News:MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO 3Health News:MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO 4Health News:Experts to develop national response to growing crisis of premature birth 2Health News:Pigs raised without antibiotics more likely to carry bacteria, parasites 2Health News:Pigs raised without antibiotics more likely to carry bacteria, parasites 3Health News:Pigs raised without antibiotics more likely to carry bacteria, parasites 4Health News:Golimumab Eases Rheumatoid Arthritis Symptoms 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: